Clinical trial
Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
NCT00343980 · Novo Nordisk A/S, Industry · Terminated
Key facts
| NCT number | NCT00343980 |
|---|---|
| Title | Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes |
| Official title | Safety and Efficacy of Inhaled Pre-prandial Human Insulin Plus Glimepiride Versus Rosiglitazone Plus Glimepiride in Type 2 Diabetes |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | rosiglitazone, inhaled human insulin, glimepiride |
| Enrollment | 363 |
| Start date | Oct 10, 2006 |
| Primary completion | Mar 10, 2008 |
| Completion | Mar 10, 2008 |
| First posted | Jun 23, 2006 |
| Last update posted | Mar 1, 2017 |
| Countries | Australia, Croatia, India, North Macedonia, Philippines, Russia, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: